We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Healthcare Growth Help STE Beat on Q1 Earnings?
Read MoreHide Full Article
Key Takeaways
STE's Q1 EPS estimate of $2.32 suggests 14.3% growth from the year-ago quarter.
STE's Healthcare and AST segments are expected to post revenue gains of 5.1% and 6.3%, respectively.
STE's Life Sciences sales may rise 5.5% as mix, pricing, and divestiture aid margins despite capital softness.
STERIS plc (STE - Free Report) is scheduled to release first-quarter fiscal 2026 results on Aug. 7, after market close.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of $2.74, which surpassed the Zacks Consensus Estimate by 5.79%. STE beat on earnings in three of the trailing four quarters and met once, delivering an average surprise of 2.05%.
Q1 Estimates for STE
The Zacks Consensus Estimate for revenues is pegged at $1.36 billion, suggesting an increase of 6.2% from the year-ago reported figure.
The Zacks Consensus Estimate for EPS is pegged at $2.32, indicating a year-over-year increase of 14.3%.
Estimate Revision Trend Ahead of STE's Q1 Earnings
Estimates for earnings have remained constant at $2.32 per share in the past 30 days.
Let's take a look at how things might have shaped up for the MedTech major prior to the announcement.
Healthcare
In the previous quarter, growth across consumables and services was robust, favored by procedure volumes in the United States as well as price and market share gains. We expect this trend to have continued in the fiscal first quarter as well.
The company, however, maintains confidence in recurring revenue streams and backlog strength. This should get reflected in the first-quarter results. In the to-be-reported quarter, within Healthcare capital equipment, order growth is expected to have remained robust despite ongoing shipment issues due to customer project delays.
Our model projects the segment’s revenues to improve 5.1% from the year-ago reported figure.
Applied Sterilization Technologies (“AST”)
In the fiscal first quarter, Steris is expected to have experienced organic revenue growth within this segment. Also, in the previous quarter, capital equipment shipments more than doubled compared to the prior year, which exceeded the company’s expectations. We expect this trend to have continued in the fiscal first quarter. In line with this, global MedTech customers are once again expected to have remained stable and the company is likely to have experienced an increase in bioprocessing demand. We expect these to have contributed to STE’s top-line performance in the to-be-reported quarter.
Per our model, AST segment’s revenues for the quarter are likely to increase 6.3% year over year.
The segment's fiscal fourth-quarter 2025 revenues declined year over year as strong growth in consumables and services was offset by a decline in capital equipment revenue. This trend might have continued in the to-be-reported quarter. However, the segment’s margin is expected to have benefited from a favorable mix, pricing, and the divestiture of the CECS business in the to-be-reported quarter.
Our model projects the segment’s revenues to increase 5.5% year over year.
What Our Model Suggests for STE
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating on earnings, which is not the case here.
Earnings ESP: STERIS has an Earnings ESP of -3.24%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3.
Stocks Worth a Look
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle.
EXAS’ earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 48.8%. As per the Zacks Consensus Estimate, the company’s second-quarter EPS may increase 77.8% from the year-ago quarter’s figure.
Cencora(COR - Free Report) has an Earnings ESP of +1.49% and a Zacks Rank #2 at present. The company is slated to release third-quarter fiscal 2025 results on Aug. 6.
The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.00%. The Zacks Consensus Estimate for fiscal third-quarter EPS implies a year-over-year increase of 13.2%.
Cardinal Health (CAH - Free Report) has an Earnings ESP of +0.68% and a Zacks Rank #2 at present. The company is expected to release fiscal fourth-quarter 2025 results on Aug. 12.
CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.30%. The Zacks Consensus Estimate for fiscal fourth-quarter EPS suggests a year-over-year improvement of 1.3%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Will Healthcare Growth Help STE Beat on Q1 Earnings?
Key Takeaways
STERIS plc (STE - Free Report) is scheduled to release first-quarter fiscal 2026 results on Aug. 7, after market close.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of $2.74, which surpassed the Zacks Consensus Estimate by 5.79%. STE beat on earnings in three of the trailing four quarters and met once, delivering an average surprise of 2.05%.
Q1 Estimates for STE
The Zacks Consensus Estimate for revenues is pegged at $1.36 billion, suggesting an increase of 6.2% from the year-ago reported figure.
The Zacks Consensus Estimate for EPS is pegged at $2.32, indicating a year-over-year increase of 14.3%.
Estimate Revision Trend Ahead of STE's Q1 Earnings
Estimates for earnings have remained constant at $2.32 per share in the past 30 days.
Let's take a look at how things might have shaped up for the MedTech major prior to the announcement.
Healthcare
In the previous quarter, growth across consumables and services was robust, favored by procedure volumes in the United States as well as price and market share gains. We expect this trend to have continued in the fiscal first quarter as well.
The company, however, maintains confidence in recurring revenue streams and backlog strength. This should get reflected in the first-quarter results. In the to-be-reported quarter, within Healthcare capital equipment, order growth is expected to have remained robust despite ongoing shipment issues due to customer project delays.
Our model projects the segment’s revenues to improve 5.1% from the year-ago reported figure.
Applied Sterilization Technologies (“AST”)
In the fiscal first quarter, Steris is expected to have experienced organic revenue growth within this segment. Also, in the previous quarter, capital equipment shipments more than doubled compared to the prior year, which exceeded the company’s expectations. We expect this trend to have continued in the fiscal first quarter. In line with this, global MedTech customers are once again expected to have remained stable and the company is likely to have experienced an increase in bioprocessing demand. We expect these to have contributed to STE’s top-line performance in the to-be-reported quarter.
Per our model, AST segment’s revenues for the quarter are likely to increase 6.3% year over year.
STERIS plc Price and EPS Surprise
STERIS plc price-eps-surprise | STERIS plc Quote
Life Sciences
The segment's fiscal fourth-quarter 2025 revenues declined year over year as strong growth in consumables and services was offset by a decline in capital equipment revenue. This trend might have continued in the to-be-reported quarter. However, the segment’s margin is expected to have benefited from a favorable mix, pricing, and the divestiture of the CECS business in the to-be-reported quarter.
Our model projects the segment’s revenues to increase 5.5% year over year.
What Our Model Suggests for STE
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating on earnings, which is not the case here.
Earnings ESP: STERIS has an Earnings ESP of -3.24%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3.
Stocks Worth a Look
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle.
Exact Sciences (EXAS - Free Report) has an Earnings ESP of +475.00% and a Zacks Rank #2 at present. The company is slated to release second-quarter 2025 results on Aug. 6. You can see the complete list of today’s Zacks #1 Rank stocks here.
EXAS’ earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 48.8%. As per the Zacks Consensus Estimate, the company’s second-quarter EPS may increase 77.8% from the year-ago quarter’s figure.
Cencora (COR - Free Report) has an Earnings ESP of +1.49% and a Zacks Rank #2 at present. The company is slated to release third-quarter fiscal 2025 results on Aug. 6.
The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 6.00%. The Zacks Consensus Estimate for fiscal third-quarter EPS implies a year-over-year increase of 13.2%.
Cardinal Health (CAH - Free Report) has an Earnings ESP of +0.68% and a Zacks Rank #2 at present. The company is expected to release fiscal fourth-quarter 2025 results on Aug. 12.
CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 10.30%. The Zacks Consensus Estimate for fiscal fourth-quarter EPS suggests a year-over-year improvement of 1.3%.